drugset / Trial / NCT03374670
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
RandomizedParallel-groupOpen-labelTreatment
Summary
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy
Timeline
- Start
- 2018-11
- Primary completion
- 2019-12
- Completion
- 2019-12
Outcome
Outcome not reported
Stopped (Enrollment): “No patients were enrolled. Study terminated for portfolio reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avacincaptad Pegol | Aptamer | — | Intravitreal |
| Background | Aflibercept | Protein / enzyme biologic | 2 mg | — |
Indications
No indication recorded.